Alvotech Stock Price, News & Analysis

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has appointed Patrik Ling as VP of Investor Relations Scandinavia, based in Stockholm. Ling brings over 25 years of life-science industry experience, most recently serving as Senior Equity Analyst at DNB Carnegie where he covered life science companies including Alvotech.

The appointment aligns with Alvotech's strategy to expand its Scandinavian shareholder base and strengthen its position as a leading Nordic life science company. Ling's background spans both pharmaceutical and financial sectors, including roles in marketing, sales, portfolio management, and equity analysis.

Alvotech (NASDAQ: ALVO), a global biotech company, has secured improved terms on its senior secured term loan facility. The company's lenders, including GoldenTree Asset Management, have agreed to reduce interest rates, resulting in estimated savings of $8.2 million in interest payments over the first 12 months.

The facility, which matures in July 2029, will be consolidated into a single tranche with an interest rate of SOFR plus 6.0% per annum, down from previous rates of SOFR plus 6.5% and 10.5%. The total facility balance stands at $1,081 million, with the company maintaining a cash balance of $152 million as of June 25, 2025.

Alvotech (NASDAQ: ALVO) reported strong financial results for H1 2025, highlighted by a 210% year-over-year increase in product revenue to $204.7 million. The company achieved its best quarter ever in operating cash flows and expanded its commercial partnerships.

Key developments include the acquisition of Xbrane's R&D facilities in Sweden and Ivers-Lee Group in Switzerland, strengthening its end-to-end biosimilars platform. The company successfully listed on Nasdaq Stockholm, completed two SDR offerings raising approximately SEK 789 million, and amended its term loan to reduce interest expenses by $8.2 million annually.

Financial highlights include $151.5 million in cash, operating profit of $28.6 million, and net profit of $141.7 million ($0.50 per share). The company also expanded partnerships with Advanz Pharma and Dr. Reddy's Laboratories for multiple biosimilar candidates.

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has scheduled its first half 2025 financial results announcement. The company will release its financial results for the period ending June 30, 2025 after U.S. markets close on August 13, 2025.

A conference call and webcast to discuss the results and business highlights will be held on August 14, 2025, at 8:00 am EDT. The presentation will be accessible through Alvotech's investor portal, with a replay available for 90 days following the event.

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has appointed Linda Jónsdóttir as its new Chief Financial Officer. Linda brings extensive experience from various industries, including a 15-year tenure at Marel where she served in multiple senior roles including CFO and COO. She succeeds Joel Morales, who has served as CFO since 2020 and will transition to an advisory role.

The leadership change comes as Alvotech continues its evolution from a privately held, R&D-focused company to a public, profitable, and fully integrated global commercial biosimilars enterprise. Joel will support the transition period and assist in preparing the company's Q2 results presentation in August.

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has announced the acquisition of Ivers-Lee Group, a Swiss pharmaceutical assembly and packaging services provider. The acquisition integrates Ivers-Lee's operations into Alvotech's Technical Operations division while maintaining it as a separate legal entity.

The strategic move comes as Alvotech prepares to launch three new biosimilars in 2025. Ivers-Lee's GMP-licensed and FDA-approved facility in Burgdorf, Switzerland, along with its unit in Lörrach, Germany, will provide capabilities including assembly and packaging of autoinjectors, pre-filled syringes, safety devices, and vials. Peter Schüpbach, Ivers-Lee's managing director, will join Alvotech's Technical Operations senior leadership team while continuing to lead Ivers-Lee.

Alvotech (NASDAQ: ALVO) has announced the acquisition of Ivers-Lee Group, a Swiss pharmaceutical assembly and packaging services company. The strategic acquisition integrates Ivers-Lee's operations into Alvotech's Technical Operations division while maintaining it as a separate legal entity.

The acquisition comes as Alvotech prepares to launch three new biosimilars in 2025. Ivers-Lee, founded in 1947, operates from Burgdorf, Switzerland and Lörrach, Germany. Peter Schüpbach, the founder's grandson, will continue as managing director and join Alvotech's Technical Operations leadership team.

The GMP-licensed and FDA-approved Burgdorf facility will provide capabilities including assembly and packaging of autoinjectors, pre-filled syringes, safety devices, and vials. Ivers-Lee will continue serving existing clients and providing CMO services.

Alvotech S.A. has announced that its treasury holdings have increased significantly, with the company now holding 6.73% of its own shares as of June 25, 2025. This represents 22,484,087 shares out of a total of 334,038,147 shares with voting rights, surpassing the 5% threshold that requires disclosure under Luxembourg transparency laws.

Alvotech (NASDAQ: ALVO) reported strong Q1 2025 financial results, with total revenues reaching $132.8 million, a 260% increase year-over-year. Product revenues surged 786% to $109.9 million, while Adjusted EBITDA improved to $20.5 million from negative $38.4 million in 2023.

The company increased its full-year guidance to $600-$700 million in revenue and $200-280 million in adjusted EBITDA, following the acquisition of Xbrane's R&D operations and rights to a proposed Cimzia biosimilar. Notable achievements include the U.S. launch of SELARSDI™ (ustekinumab-aekn), a Stelara® biosimilar, and BLA filing acceptances for biosimilars to Simponi®, Eylea®, and Prolia/Xgeva.

The company reported a net profit of $109.7 million ($0.39 per share) and expects to be free cash-flow positive in 2025.